{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:51:42Z","timestamp":1793235102982,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Declining efficacy of chloroquine against <jats:italic>Plasmodium vivax<\/jats:italic> malaria has been documented in Ethiopia. Thus, there is a need to assess the efficacy of alternative schizontocidal anti-malarials such as dihydroartemisinin\u2013piperaquine (DHA\u2013PPQ) in <jats:italic>P. vivax<\/jats:italic> malaria-infected patients. This study was conducted to evaluate the therapeutic efficacy of DHA\u2013PPQ drug in South West Ethiopia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a single-arm, prospective therapeutic efficacy study in patients with uncomplicated <jats:italic>P. vivax<\/jats:italic> malaria. The study was conducted from May 2021 to August 2021, based on the standard World Health Organization study protocol for surveillance of anti-malarial therapeutic efficacy. The study endpoint was adequate clinical and parasitological response on day 42.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 86 patients with uncomplicated vivax malaria were enrolled. Of these, 79 patients completed the scheduled follow up; all showing adequate clinical and parasitological responses to day 42, with a successful cure rate of 100% (95% CI 96\u2013100). Parasitaemias were cleared rapidly (86% by day 1 and 100% by day 3), as were clinical symptoms (100% by day 1). Gametocyte carriage decreased from 44% on Day 0 to 1% on day 1 and 0% on Day 2. Mean haemoglobin concentrations increased between day 0 (mean 12.2\u00a0g\/dL) and day 42 (mean 13.3\u00a0g\/dL). Treatment was well tolerated and no severe adverse events were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In summary, treatment with DHA\u2013PPQ demonstrated excellent efficacy for uncomplicated <jats:italic>P. vivax<\/jats:italic>, with no recurrences to day 42, and no safety concerns. This treatment, which is also effective against <jats:italic>P. falciparum<\/jats:italic>, appears to be an ideal alternative for <jats:italic>P. vivax<\/jats:italic> as part of the malaria elimination programme.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04380-7","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T20:07:59Z","timestamp":1669579679000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic efficacy of dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia"],"prefix":"10.1186","volume":"21","author":[{"given":"Hussein","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heven","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henok","family":"Hailgiorgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kale","family":"Gubae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mebrahtom","family":"Haile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiwot","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede","family":"Etana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Girma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worku","family":"Bekele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melkie","family":"Chernet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getachew","family":"Tollera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geremew","family":"Tasew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokretsion","family":"Gidey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Commons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashenafi","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"4380_CR1","unstructured":"Ethiopian Public Health Institute. Ethiopia National Malaria Indicator Survey; 2016."},{"key":"4380_CR2","unstructured":"Ethiopia malaria elimination strategic plan: 2020\u20132025. Addis Ababa; 2020."},{"key":"4380_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0140-6736(19)31096-7","volume":"394","author":"KE Battle","year":"2019","unstructured":"Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000\u201317: a spatial and temporal modelling study. Lancet. 2019;394:332\u20134.","journal-title":"Lancet"},{"key":"4380_CR4","volume-title":"National Malaria Elimination Road Map","author":"Ministry of Health","year":"2017","unstructured":"Ministry of Health. National Malaria Elimination Road Map. Addis Ababa: Ministry of Health; 2017."},{"key":"4380_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(86)91945-8","volume":"328","author":"A Teklehaimanot","year":"1986","unstructured":"Teklehaimanot A, Alene GD, Bennett S. Chloroquine-resistant Plasmodium falciparum malaria in Ethiopia. Lancet. 1986;328:127\u20139.","journal-title":"Lancet"},{"key":"4380_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1365-3156.1996.tb00115.x","volume":"1","author":"GD Alene","year":"1996","unstructured":"Alene GD, Bennett S. Chloroquine resistance of Plasmodium falciparum malaria in Ethiopia and Eritrea. Trop Med Int Health. 1996;1:810\u20135.","journal-title":"Trop Med Int Health"},{"key":"4380_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14787210.2016.1220304","volume":"4","author":"CS Chu","year":"2016","unstructured":"Chu CS, White NJ. Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther. 2016;4:885\u2013900.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4380_CR8","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"4380_CR9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.4269\/ajtmh.20-0186","volume":"103","author":"RJ Commons","year":"2020","unstructured":"Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the proportion of Plasmodium vivax recurrences caused by relapse. A systematic reviews and meta-analysis. Am J Med Hyg. 2020;103:1094\u20139.","journal-title":"Am J Med Hyg"},{"key":"4380_CR10","volume-title":"National malaria guidelines","author":"Ministry of Health Ethiopia","year":"2022","unstructured":"Ministry of Health Ethiopia. National malaria guidelines. 5th ed. Addis Ababa: Ministry of Health; 2022.","edition":"5"},{"key":"4380_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1186\/s12936-015-1041-4","volume":"14","author":"S Getachew","year":"2015","unstructured":"Getachew S, Thriemer K, Auburn S, Abera A, Gadisa E, Aseffa A, et al. Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malar J. 2015;14:525.","journal-title":"Malar J"},{"key":"4380_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-3305-4-46","volume":"4","author":"T Ketema","year":"2011","unstructured":"Ketema T, Getahun K, Bacha K. Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia. Parasit Vectors. 2011;4:46.","journal-title":"Parasit Vectors"},{"key":"4380_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4269\/ajtmh.2011.09-0723","volume":"84","author":"AM Yohannes","year":"2011","unstructured":"Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg. 2011;84:137\u201340.","journal-title":"Am J Trop Med Hyg"},{"key":"4380_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1475-2875-7-220","volume":"7","author":"H Teka","year":"2008","unstructured":"Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, et al. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J. 2008;7:220.","journal-title":"Malar J"},{"key":"4380_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pctr.0020020","volume":"18","author":"MR Kamya","year":"2007","unstructured":"Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, et al. Artemether-lumefantrine versus dihydroartemisinin\u2013piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007;18: e20.","journal-title":"PLoS Clin Trials"},{"key":"4380_CR16","volume-title":"Malaria biology in the era of eradication","author":"DF Wirth","year":"2017","unstructured":"Wirth DF, Alonso PL. Malaria biology in the era of eradication. Woodbury: Cold Spring Harbor Perspectives in medicine; 2017."},{"key":"4380_CR17","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3201\/eid2408.170768","volume":"24","author":"J Popovici","year":"2018","unstructured":"Popovici J, Vantaux A, Primault L, Samreth R, Por Piv E, Bin S, et al. Therapeutic and transmission-blocking efficacy of dihydroartemisinin\/piperaquine and chloroquine against Plasmodium vivax malaria, Cambodia. Emerg Infect Dis. 2018;24:1516\u20139.","journal-title":"Emerg Infect Dis"},{"key":"4380_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.4269\/ajtmh.12-0745","volume":"89","author":"F Massebo","year":"2013","unstructured":"Massebo F, Balkew M, Gebre-Michael T, Lindtj\u00f8rn B. Entomologic inoculation rates of Anopheles arabiensis in Southwestern Ethiopia. Am J Trop Med Hyg. 2013;89:466\u201373.","journal-title":"Am J Trop Med Hyg"},{"key":"4380_CR19","volume-title":"Ethiopia Malaria Elimination Strategic Plan: 2021\u20132025, towards a malaria-free Ethiopia","author":"Federal Ministry of Health of Ethiopia","year":"2021","unstructured":"Federal Ministry of Health of Ethiopia. Ethiopia Malaria Elimination Strategic Plan: 2021\u20132025, towards a malaria-free Ethiopia. Addis Ababa: Federal Ministry of Health of Ethiopia; 2021."},{"key":"4380_CR20","volume-title":"Methods for surveillance of anti-malarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of anti-malarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"4380_CR21","volume-title":"Basic malaria microscopy. Part I. Learner's guide","author":"WHO","year":"2010","unstructured":"WHO. Basic malaria microscopy. Part I. Learner\u2019s guide. 2nd ed. Geneva: World Health Organization; 2010.","edition":"2"},{"key":"4380_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002928","volume":"16","author":"RJ Commons","year":"2019","unstructured":"Commons RJ, Simpson JA, Thriemer K, Abreha T, Adam I, Nicholas M, et al. The efficacy of dihydroartemisinin\u2013piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: a systematic review and individual patient data meta-analysis. PLoS Med. 2019;16: e1002928.","journal-title":"PLoS Med"},{"key":"4380_CR23","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0804915","volume":"359","author":"HA Karunajeewa","year":"2008","unstructured":"Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008;359:2545\u201357.","journal-title":"N Engl J Med"},{"key":"4380_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12916-019-1386-6","volume":"17","author":"RJ Commons","year":"2019","unstructured":"Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, et al. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Med. 2019;17:151.","journal-title":"BMC Med"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04380-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T20:08:17Z","timestamp":1669579697000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04380-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4380"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04380-7","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received ethical approval from the scientific and ethical review board of Ethiopian Public Health Institute (protocol approval number EPHIIRB-294\/2022. Written informed consent was obtained from all of the study participants\u2009\u2265\u200918\u00a0years of age or by parents or guardians of children less than 18\u00a0years of age, with children 12\u201317\u00a0years of age providing written informed assent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"351"}}